Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 601–650 of 1,441 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT03473457	CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia(AML)	N/A	terminated	Mar 22, 2018	Zhujiang Hospital	The therapeutic effect was not as expected	Other (stated, no rule matched)
NCT01439347	A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With…	Phase 3	terminated	Sep 23, 2011	Spectrum Pharmaceuticals, Inc	Sponsor decision	Sponsor / business decision
NCT01045382	MSC and HSC Coinfusion in Mismatched Minitransplants	Phase 2	terminated	Jan 11, 2010	University of Liege	recruitment too slow	Enrollment / accrual
NCT03742323	REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia	Phase 1 / Phase 2	terminated	Nov 15, 2018	PETHEMA Foundation	Because of low recruitment	Enrollment / accrual
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+…	Phase 1 / Phase 2	terminated	Mar 5, 2013	Northwestern University	Lack of funding	Funding
NCT02105116	AML Therapy With Irradiated Allogeneic Cells	N/A	terminated	Apr 7, 2014	Rutgers, The State University of New Jersey	No patients were eligible to receive the experimental component of the protocol therapy.	Other (stated, no rule matched)
NCT01663766	Phase I Study of Milatuzumab for Graft Versus Host Disease	Phase 1	terminated	Aug 13, 2012	Gilead Sciences	PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD…	Safety / toxicity
NCT01728207	Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL	Phase 1	terminated	Nov 19, 2012	Gilead Sciences	Study was stopped due to insufficient efficacy and very slow accrual	Efficacy / futility
NCT02229266	Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy…(HINKL)	Phase 2	terminated	Sep 1, 2014	Technische Universität Dresden	low recruitment rate	Enrollment / accrual
NCT04217720	SNS-301 Monotherapy in High Risk MDS and CMML	Phase 2	withdrawn	Jan 3, 2020	Sensei Biotherapeutics, Inc.	Sponsor decision	Sponsor / business decision
NCT01113502	Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)	Phase 1 / Phase 2	terminated	Apr 30, 2010	Abramson Cancer Center at Penn Medicine	not stated	Not stated
NCT00449761	Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia…	Phase 2	terminated	Mar 21, 2007	Novartis Pharmaceuticals	not stated	Not stated
NCT02928510	Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic…	—	terminated	Oct 10, 2016	Jonsson Comprehensive Cancer Center	withdrawn by sponsor	Other (stated, no rule matched)
NCT04296214	Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic…	—	withdrawn	Mar 5, 2020	Grupo Cooperativo de Hemopatías Malignas	Poor recruitment	Enrollment / accrual
NCT02440568	AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in…	Phase 1 / Phase 2	terminated	May 12, 2015	University of Illinois at Chicago	not stated	Not stated
NCT03602898	Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate…	Phase 2	withdrawn	Jul 27, 2018	Fred Hutchinson Cancer Center	Insufficient funding	Funding
NCT01486784	A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute…	Phase 1 / Phase 2	terminated	Dec 7, 2011	Abramson Cancer Center at Penn Medicine	not stated	Not stated
NCT03806192	Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid…	N/A	terminated	Jan 16, 2019	University of Washington	Terminated due to insufficient funding	Funding
NCT00914628	Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients…(TK008)	Phase 3	terminated	Jun 5, 2009	AGC Biologics S.p.A.	EMA withdrew the marketing Authorisation at the request of AGC Biologics S.p.A (formerly MolMed…	Other (stated, no rule matched)
NCT04395092	Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and…	Phase 2	withdrawn	May 20, 2020	Kiadis Pharma	The sponsor decided to withdraw this study	Sponsor / business decision
NCT00967343	Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host…	Phase 2 / Phase 3	terminated	Aug 27, 2009	Kiadis Pharma	not stated	Not stated
NCT03579888	CD19-Specific T Cells Post AlloSCT	Phase 1	terminated	Jul 9, 2018	M.D. Anderson Cancer Center	Study halted prematurely	Other (stated, no rule matched)
NCT02669264	Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute…	Phase 1	terminated	Feb 1, 2016	ADC Therapeutics S.A.	The study was early terminated prior to part 2 because of slow accrual.	Enrollment / accrual
NCT01131325	Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148)	Phase 4	terminated	May 26, 2010	Novartis Pharmaceuticals	not stated	Not stated
NCT01644253	Phase 1b Safety and Efficacy Study of TRU-016	Phase 1	terminated	Jul 19, 2012	Aptevo Therapeutics	Business decision	Sponsor / business decision
NCT00003056	Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma…	Phase 3	terminated	May 24, 2004	Baxalta now part of Shire	Interim analysis indicated study should be terminated	Efficacy / futility
NCT02341209	Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL)	Phase 2	terminated	Jan 19, 2015	Rochester General Hospital	Low enrollment	Enrollment / accrual
NCT03066466	Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD…	Phase 3	withdrawn	Feb 28, 2017	Loyola University	No participants were enrolled	Enrollment / accrual
NCT02089230	MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor…	Phase 1 / Phase 2	terminated	Mar 17, 2014	M.D. Anderson Cancer Center	The trial was terminated due to slow accrual	Enrollment / accrual
NCT01599429	Study of the Predictive Marker FLT in Patients Suffering From AML(TEP-FLT-LMA)	—	withdrawn	May 16, 2012	Centre de recherche du Centre hospitalier universitaire de Sherbrooke	No participants enrolled	Enrollment / accrual
NCT01685411	Busulfan and Cyclophosphamide Followed By ALLO BMT	N/A	terminated	Sep 14, 2012	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT03094611	Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive…	Phase 2	terminated	Mar 29, 2017	M.D. Anderson Cancer Center	the study was closed early due to competing trials	Other (stated, no rule matched)
NCT02336048	A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care…	Phase 1	terminated	Jan 12, 2015	Hoffmann-La Roche	This study was terminated early because premedication with tocilizumab was unlikely to reduce the…	Other (stated, no rule matched)
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With…	Phase 1	terminated	Sep 5, 2012	Fred Hutchinson Cancer Center	Terminated due to low accrual.	Enrollment / accrual
NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory…	Phase 1	withdrawn	Jul 30, 2018	Children's Hospital Medical Center, Cincinnati	Lack of enrollment due to the availability of other novel salvage therapies for relapsed/refractory…	Enrollment / accrual
NCT03301597	NLA101 in Adults Receiving High Dose Chemotherapy for AML(LAUNCH)	Phase 2	terminated	Oct 4, 2017	Nohla Therapeutics, Inc.	Development plan under review.	Other (stated, no rule matched)
NCT03125876	A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)	Phase 1	terminated	Apr 24, 2017	Sunshine Lake Pharma Co., Ltd.	Company strategy adjustment	Sponsor / business decision
NCT03360006	A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With…	Phase 1	terminated	Dec 2, 2017	AbbVie	Strategic Reasons	Sponsor / business decision
NCT02648932	The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With…	Phase 2	terminated	Jan 7, 2016	University of Chicago	Poor accrual	Enrollment / accrual
NCT00439296	ABT-751 With Chemotherapy for Relapsed Pediatric ALL	Phase 1 / Phase 2	terminated	Feb 23, 2007	Therapeutic Advances in Childhood Leukemia Consortium	The study was stopped due to poor accrual and lack of funding.	Enrollment / accrual
NCT04342117	Observational Trial of Real-World Treatment Utilization and Effectiveness of…(REAL)	—	terminated	Apr 10, 2020	SecuraBio	Strategy Change	Sponsor / business decision
NCT03113071	Safety and Activity of Digoxin With Decitabine in Adult AML and MDS	Phase 1 / Phase 2	terminated	Apr 13, 2017	Fox Chase Cancer Center	Slow accrual	Enrollment / accrual
NCT03881735	Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With…	Phase 2	withdrawn	Mar 19, 2019	Roswell Park Cancer Institute	no accrual	Enrollment / accrual
NCT02973711	A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML	Phase 1 / Phase 2	withdrawn	Nov 25, 2016	University of Michigan Rogel Cancer Center	lack of funding	Funding
NCT03515707	Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal…	Phase 2	withdrawn	May 3, 2018	Fred Hutchinson Cancer Center	PI recommended closure	Other (stated, no rule matched)
NCT00176930	Stem Cell Transplant for Hematological Malignancy	N/A	terminated	Sep 15, 2005	Masonic Cancer Center, University of Minnesota	replaced by another study ; Trial re-written as MT2015-29	Other (stated, no rule matched)
NCT03601819	Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	Phase 1	terminated	Jul 26, 2018	University of Michigan Rogel Cancer Center	Low accrual	Enrollment / accrual
NCT02309515	Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic…	Phase 2	terminated	Dec 5, 2014	Mayo Clinic	Slow Accrual	Enrollment / accrual
NCT01827930	Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on…(MIM)	Phase 3	terminated	Apr 10, 2013	Institut Bergonié	Difficulties of enrolment of Patient	Enrollment / accrual
NCT00615784	Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407)	Phase 2	terminated	Feb 14, 2008	Abramson Cancer Center at Penn Medicine	Study terminated. Eisai's Targretin acquired by another pharmaceutical company.	Sponsor / business decision

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Sep 13, 2021source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules